BioCryst (BCRX) Partner In Japan Files NDA for Peramivir
More News related to BCRX
- Swine Flu Cases Decline to Lowest Level in 2+ Months
- Positives Seen On BioCryst (BCRX) After Peramivir Granted Priority Review In Japan
- BioCryst Pharma (BCRX) Priced 5M Common Offering at $9.75/Share
- BioCryst Announces Pricing of Public Offering of Common Stock
- Momentum Mover BioCryst (BCRX) Down On Stock Offering
More News related to FDA
- After Month's Of Gains, Gold Gives A Little Back Today (GDX, GLD, DGL, More)
- Office Supplies Cos. Up On Jobs Report: OMX, SPLS, ODP
- Synovus Financial (SNV) Running Up on FBR Upgrade
- Staffing Service Stocks Higher As Job Creation Now In Sight: MAN, MWW, RHI, KELYA, TBI, SFN, ASGN
- Novartis for Alcon (ACL)? Novartis Says "No" But Market Says "Yes"
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced that its partner, Shionogi & Co., Ltd. has filed a New Drug Application (NDA) in Japan to seek regulatory approval for intravenous (i.v.) peramivir to treat patients with influenza.
As a consequence of this filing, BioCryst will receive a regulatory milestone payment of $7 million under its agreement with Shionogi.
Related Categories
FDAStocks Mentioned
-0.24Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
